Menu Search
Equities

GSK plc

GSK:NYQ

GSK plc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)33.70
  • Today's Change0.35 / 1.05%
  • Shares traded23.36k
  • 1 Year change-4.75%
  • Beta0.6522
Data delayed at least 15 minutes, as of Nov 22 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy1
Outperform1
Hold5
Sell1
Strong Sell0

Share price forecast in USD

The 6 analysts offering 12 month price targets for GSK plc (ADR) have a median target of 43.55, with a high estimate of 46.00 and a low estimate of 37.00. The median estimate represents a 29.23% increase from the last price of 33.70.
High36.5%46.00
Med29.2%43.55
Low9.8%37.00

Dividends in USD

Historical dividend information is not available for GSK plc.
Div growth (TTM)--
More ▼

Earnings history & estimates in USD

On Oct 30, 2024, GSK plc (ADR) reported 3rd quarter 2024 earnings of 1.29 per share. This result was in line with the consensus of the 2 analysts following the company and exceeded last year's 3rd quarter results by 1.25%.
The next earnings announcement is expected on Feb 05, 2025.
Average growth rate+6.70%
GSK plc (ADR) reported annual 2023 earnings of 3.86 per share on Jan 31, 2024.
Average growth rate-0.18%
More ▼

Revenue history & estimates in USD

GSK plc (ADR) had 3rd quarter 2024 revenues of 10.41bn. This missed the 10.78bn consensus estimate of the 3 analysts following the company. This was 23.30% above the prior year's 3rd quarter results.
Average growth rate+0.40%
GSK plc (ADR) had revenues for the full year 2023 of 37.70bn. This was 4.43% above the prior year's results.
Average growth rate-2.45%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.